Conversion from Cyclosporin A to Tacrolimus as a Non‐Surgical Alternative to Reduce Gingival Enlargement: A Preliminary Case Series
Authors:
- Gonzalo HernándezGHGonzalo Hernández
- Lorenzo ArribaLALorenzo Arriba
- María Cruz FríasMFMaría Cruz Frías
- José Carlos de la MacorraJMJosé Carlos de la Macorra
- Juan Carlos de VicenteJVJuan Carlos de Vicente
- Carlos JiménezCJCarlos Jiménez
- Amado de AndrésAAAmado de Andrés
- Enrique MorenoEMEnrique Moreno
- 1 December 2003
- journal article
- Published by Wiley in Journal of Periodontology
- Vol. 74 (12) , 1816-1823
Abstract
Background: Gingival enlargement (GE) is a frequent side effect that occurs in organ transplant recipients (OTR) after the administration of cyclosporin A (CsA). The availability of new drugs used to suppress graft rejection in OTR offers an opportunity to manage GE non‐surgically. This preliminary case series aimed to analyze the effect of CsA withdrawal and its substitution by another immunosuppressant in OTR with severe GE.Methods: Four organ transplant recipients who had received a liver or renal allograft were recruited for this study. All OTR had developed clinically severe CsA‐induced GE. GE scores were assessed for each patient at baseline and at weeks 2, 4, 8, 12, 16, and 54 following conversion to tacrolimus. Scaling and root planing were initially performed and repeated monthly during the first 6 months. Careful polishing of the teeth was carried out once every 2 weeks until month 6 and then monthly until month 12. Hygiene instructions and reinforcement to optimize oral hygiene were maintained throughout the study.Results: The four patients showed a rapid decrease in their gingival symptoms and in the size of the gingivae. This change was clinically evident 8 weeks after conversion to tacrolimus. One year later, all the patients experienced GE regression, although some anatomic irregularities persisted in the interdental papillae of one of the patients. No adverse effects from tacrolimus were observed during the study except in one patient who presented headaches.Conclusion: It seems that CsA withdrawal and its conversion to tacrolimus in organ transplant recipients who develop severe gingival enlargement, together with an extensive plaque control program, provide an effective means to control/eliminate gingival hyperplasia, hyperplasia, with minimal risk of graft dysfunction. J Periodontol 2003;74:1816‐1823.Keywords
This publication has 32 references indexed in Scilit:
- The value of switching from cyclosporine to tacrolimus in the treatment of refractory acute rejection and obliterative bronchiolitis after lung transplantationTransplant International, 2002
- Identification of a Site on Mannan-binding Lectin Critical for Enhancement of PhagocytosisJournal of Biological Chemistry, 2001
- Photographic scoring of gingival overgrowthJournal of Clinical Periodontology, 2001
- Reduction of Severe Gingival Overgrowth in a Kidney Transplant Patient by Replacing Cyclosporin A With TacrolimusJournal of Periodontology, 2000
- Human gingival glycosaminoglycans in cyclosporin‐induced overgrowthJournal of Periodontal Research, 2000
- Effectiveness of Periodontal Therapy in Patients With Drug‐Induced Gingival Overgrowth. Long‐Term ResultsJournal of Periodontology, 1999
- Clinical Effects of Periodontal Therapy on the Severity of Cyclosporin A‐Induced Gingival HyperplasiaJournal of Periodontology, 1999
- TacrolimusDrugs, 1993
- Incidence and severity of phenytoin‐induced gingival overgrowth in epileptic patients in General Medical PracticeCommunity Dentistry and Oral Epidemiology, 1992
- The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patientsJournal of Clinical Periodontology, 1985